Email Address
info@myglp1store.com
Phone Number
+1 (904) 942-2327
Our Location
8102 Blanding blvd. Jacksonville, FL 32244
info@myglp1store.com
+1 (904) 942-2327
8102 Blanding blvd. Jacksonville, FL 32244
$149.99
✅ What the clinical trials show
In a Phase 2 trial in adults with overweight/obesity, participants received once-weekly subcutaneous doses of Survodutide ranging from 0.6 mg to 4.8 mg, with some groups undergoing gradual titration, compared to placebo, for up to 46 weeks.
The highest-dose group (4.8 mg) achieved a mean weight reduction of approximately –14.9% at 46 weeks (placebo-adjusted ~–12.1%).
Dosing in trials was once weekly, subcutaneous injection.
Sample titration schedule
Based on trial protocols and study designs:
Weeks 1–20: ~0.6 mg weekly initially, gradually increasing toward ~2.4–3.6 mg
Weeks 21–46: ~2.4 mg / 3.6 mg / 4.8 mg weekly for maintenance at target levels
Phase 3 design: escalation to up to ~6.0 mg weekly is being studied in ongoing trials
⚠️ Important cautions
Survodutide is not approved for weight loss in general clinical practice.
The doses above are derived from clinical trial settings only and are not official prescribing guidelines.
Long-term safety, optimal maintenance dosing, and higher-dose effects beyond the studied ranges are not fully established.
Most common side effects in trials were gastrointestinal (nausea, vomiting); discontinuation occurred in ~25% of treated participants versus ~4% of placebo.
Any off-trial use or dose escalation beyond the studied range carries significant safety, ethical, and legal risks.
This product is intended for research purposes only. It is designated strictly for in vitro testing and laboratory experimentation and is not approved for human or animal consumption. All information provided on this website is for educational and informational purposes only. This product should be handled only by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Experience the science of transformation with Survodutide 10mg, an advanced peptide formulation designed to support effective weight control and fat metabolism. Acting as a dual GLP-1 and GIP receptor agonist, this compound helps regulate appetite, stabilize blood sugar levels, and support healthy energy utilization — making it a powerful ally for individuals focused on body composition and metabolic balance.
At MYGLP1 Store, we provide authentic Survodutide 10mg Peptides from verified suppliers, ensuring exceptional quality and purity. Each vial delivers a precisely measured 10mg concentration, offering consistency and reliability for controlled usage. Designed for individuals pursuing healthier body composition and improved metabolic performance, this product delivers professional-grade quality with convenient online access.
Encourages gradual and sustainable weight management
Supports reduction of stored body fat
Helps reduce appetite and overeating tendencies
Promotes improved glucose control and insulin sensitivity
Aids in maintaining long-term metabolic balance
Premium, lab-tested Survodutide 10mg sourced from trusted facilities
Fast and secure shipping with discreet packaging
Professional customer support and responsive service
Safe online ordering and satisfaction guarantee
This peptide mimics the natural actions of GLP-1 and GIP hormones, signaling the body to regulate hunger while improving fat utilization. With consistent use, Survodutide 10mg may support visible body composition improvements when combined with balanced nutrition and regular physical activity.
Survodutide 10mg should be used under professional supervision for therapeutic purposes. Always consult a qualified healthcare provider before starting any peptide-based program.
Empower your wellness goals with Survodutide 10mg — a trusted peptide for balanced weight management and fat reduction.
Order online from MYGLP1 Store today for quality, reliability, and fast delivery.
✅ What the clinical trials show
In a Phase 2 trial in adults with overweight/obesity, participants received once-weekly subcutaneous doses of Survodutide ranging from 0.6 mg to 4.8 mg, with some groups undergoing gradual titration, compared to placebo, for up to 46 weeks.
The highest-dose group (4.8 mg) achieved a mean weight reduction of approximately –14.9% at 46 weeks (placebo-adjusted ~–12.1%).
Dosing in trials was once weekly, subcutaneous injection.
Sample titration schedule
Based on trial protocols and study designs:
Weeks 1–20: ~0.6 mg weekly initially, gradually increasing toward ~2.4–3.6 mg
Weeks 21–46: ~2.4 mg / 3.6 mg / 4.8 mg weekly for maintenance at target levels
Phase 3 design: escalation to up to ~6.0 mg weekly is being studied in ongoing trials
⚠️ Important cautions
Survodutide is not approved for weight loss in general clinical practice.
The doses above are derived from clinical trial settings only and are not official prescribing guidelines.
Long-term safety, optimal maintenance dosing, and higher-dose effects beyond the studied ranges are not fully established.
Most common side effects in trials were gastrointestinal (nausea, vomiting); discontinuation occurred in ~25% of treated participants versus ~4% of placebo.
Any off-trial use or dose escalation beyond the studied range carries significant safety, ethical, and legal risks.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.